Kristina Young
Radiation Oncology · Portland, ORNPI 1518286871
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,187 of the $1,868 with a category attached, or 63.5%. Elekta, Inc. accounts for 65.7% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $1,090, 6.6 times the $165 reported in 2021.
Across 15 payments — averaging $124.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Elekta, Inc.$1K
- Viewray Technologies Inc$400
- Siemens Medical Solutions USA, Inc.$214
- GE HealthCare$27
Across 3 payments — averaging $38,570 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$104K
- Viewray Technologies Inc$12K
What the payments were for
- Travel & lodging$68136%
- Food & beverage$1,18764%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Elekta, Inc. | 7 | $1,227 |
| Viewray Technologies Inc | 2 | $400 |
| Siemens Medical Solutions USA, Inc. | 5 | $214 |
| GE HealthCare | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,868 in reported general payments places this provider in the 80th percentile of 93 radiation oncology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lidocaine Hcl ViscousLidocaine Hcl | 18 | $506 |
| Tamsulosin Hcl | 13 | $142 |
| Omeprazole | 12 | $49 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Portland
- Marka CrittendenPortland$20K
- Steven SeungPortland$11K
- Joshua WalkerPortland$9K
- Andrew KeePortland$7K
- Brandon DyerPortland$4K
- Nima NabavizadehPortland$4K
- Amar SrivastavaPortland$4K
- Re-I ChinPortland$3K
- Akanksha RajeursPortland$2K
- Matthew SolhjemPortland$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.